Targeting a Novel ER/HOXB7 Signaling Loop in Tamoxifen-Resistant Breast Cancer

The majority of patients with breast cancer present with an estrogen receptor-positive (ER(+)) tumor, and the endocrine agent tamoxifen is a mainstay for their treatment. Unfortunately, however, resistance remains a major problem because most patients who respond eventually have a recurrence. Thus,...

Celý popis

Uložené v:
Podrobná bibliografia
Vydané v:Cancer discovery Ročník 5; číslo 9; s. 909
Hlavní autori: Heideman, Marinus R, Frei, Anna, Hynes, Nancy E
Médium: Journal Article
Jazyk:English
Vydavateľské údaje: United States 01.09.2015
Predmet:
Animals
Antineoplastic Agents, Hormonal - pharmacology
Drug Resistance, Neoplasm - genetics
Estrogen Receptor alpha - metabolism
Female
Gene Expression Regulation, Neoplastic
Homeodomain Proteins - metabolism
Humans
Receptor, ErbB-2 - metabolism
ISSN:2159-8290, 2159-8290
On-line prístup:Zistit podrobnosti o prístupe
Tagy: Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
Popis
Shrnutí:The majority of patients with breast cancer present with an estrogen receptor-positive (ER(+)) tumor, and the endocrine agent tamoxifen is a mainstay for their treatment. Unfortunately, however, resistance remains a major problem because most patients who respond eventually have a recurrence. Thus, an enduring challenge in the breast cancer field is to identify mechanisms underlying tamoxifen resistance. Jin and colleagues describe a novel ER/HOXB7 signaling loop in tamoxifen-resistant breast cancer models. Importantly, they reveal that targeting this signaling loop has great promise as an approach to treat patients with tamoxifen-resistant breast cancer.
Bibliografia:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Commentary-3
content type line 23
ISSN:2159-8290
2159-8290
DOI:10.1158/2159-8290.CD-15-0871